603127.SHG Joinn Laboratories(China)Co
- Market cap
- CNY 34.6B
- P/E
- 27.5x
- P/B
- 3.28x
- ROE
- 13.5%
- Dividend yield
- 0.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603127.SHG undervalued?
Graham number603127.SHG trades 100.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Joinn Laboratories(China)Co fundamental analysis
No fundamental analysis for Joinn Laboratories(China)Co yet.
Joinn Laboratories(China)Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Rel…
Full company profileJoinn Laboratories(China)Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Joinn Laboratories(China)Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 242M | 301M | 409M | 639M | 1.08B | 1.52B | 2.27B | 2.38B | 2.02B | 1.66B | 1.58B |
| Gross Profit | 122M | 169M | 216M | 329M | 551M | 738M | 1.08B | 982M | 521M | 343M | 435M |
| Operating Income | 53.5M | 94.2M | 126M | 216M | 361M | 643M | 1.25B | 507M | 104M | -42.1M | 40.2M |
| EBITDA | 79.9M | 108M | 134M | 215M | 342M | 490M | 803M | 677M | 180M | 483M | 1.36B |
| Net Income | 51.7M | 76.4M | 108M | 187M | 315M | 557M | 1.07B | 397M | 74.1M | 298M | 1.24B |
| EPS | 0.11 | 0.15 | 0.17 | 0.30 | 0.51 | 0.77 | 1.43 | 0.53 | 0.10 | 0.40 | 1.65 |
| Balance Sheet | |||||||||||
| Total Assets | 597M | 941M | 1.14B | 1.42B | 2.11B | 8.54B | 10.4B | 10.0B | 9.40B | 9.68B | 11.3B |
| Total Liabilities | 337M | 383M | 490M | 591M | 884M | 1.39B | 2.17B | 1.75B | 1.32B | 1.36B | 2.18B |
| Shareholders' Equity | 260M | 557M | 651M | 827M | 1.22B | 7.14B | 8.18B | 8.28B | 8.08B | 8.32B | 9.17B |
| Cash & Short-term Investments | 133M | 405M | 252M | 308M | 548M | 4.84B | 3.33B | 3.24B | 2.36B | 912M | 531M |
| Total Debt | - | - | 9.50M | 22.3M | 24.5M | 95.3M | 87.7M | 41.9M | 61.0M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 119M | 120M | 176M | 148M | 428M | 686M | 971M | 648M | 339M | 445M | - |
| Capital Expenditure | 52.4M | 25.3M | 130M | 127M | 149M | 237M | 275M | 193M | 269M | 144M | 574M |
| Free Cash Flow | 66.4M | 94.7M | 46.2M | 21.3M | 279M | 448M | 696M | 430M | 69.5M | 301M | 563M |
| Ratios | |||||||||||
| ROE | 19.9% | 13.7% | 16.6% | 22.6% | 25.7% | 7.8% | 13.1% | 4.8% | 0.9% | 3.6% | 13.5% |
| ROA | 8.7% | 8.1% | 9.5% | 13.2% | 14.9% | 6.5% | 10.4% | 4.0% | 0.8% | 3.1% | 10.9% |
| Net Profit Margin | 21.4% | 25.4% | 26.5% | 29.2% | 29.3% | 36.8% | 47.4% | 16.7% | 3.7% | 18.0% | 78.3% |
| Debt to Equity | - | - | 0.01x | 0.03x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Joinn Laboratories(China)Co dividends
- Dividend yield
- 0.06%
- Forward dividend
- 0.12 CNY
- Payout ratio
- 7.5%
- Ex-dividend date
- Jun 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 22.4M | 0.03 | 7.5% |
| 2024 | CNY 120M | 0.16 | 161.5% |
| 2023 | CNY 214M | 0.29 | 54.0% |
| 2022 | CNY 137M | 0.18 | 12.8% |
| 2021 | CNY 94.9M | 0.13 | 17.0% |
| 2020 | CNY 55.1M | 0.09 | 17.5% |
| 2019 | CNY 34.5M | 0.06 | 18.5% |
| 2018 | CNY 24.6M | 0.04 | 22.7% |
| 2017 | CNY 20.6K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jul 25, 2023.
Who owns Joinn Laboratories(China)Co
- Insiders 40.66%
- Institutions 16.28%
- Public & others 43.06%
- Shares outstanding 630M
- Free float 485M
Joinn Laboratories(China)Co company profile
- Company name
- Joinn Laboratories(China)Co
- Ticker
- 603127.SHG
- ISIN
- CNE100002W27
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 2,649
- Fiscal year end
- December
- Address
- A5 Rongjing East Street, Beijing, China, 100176
- Phone
- 86 10 6786 9966
- Website
- joinnlabs.com
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.
Joinn Laboratories(China)Co management
7- Dr. Yuxia Feng M.D.Founder & Chairman · born 1964
- Mr. Dapeng GaoGM, Secretary to the Board, Joint Company Secretary & Executive Director · born 1982
- Ms. Aishui YuChief Financial Officer · born 1976
- Mr. Jingliang GuVice GM, Head of Sales Department and Executive Director · born 1980
- Dr. Yunxia Sun DCBT, M.D.Vice GM & Executive Director · born 1968
- Ms. Xi LuoExecutive Director · born 1978
- Dr. Dalin YaoChief Scientific Officer · born 1949